SCHEMBL2238094

SCHEMBL2238094

Nc1nccc(-c2c[nH]c3ncc(Br)cc23)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 5/20 0.66
CDK5R1 Q15078 5/20 0.66
PDPK1 O15530 3/20 0.66
CCNB2 O95067 3/20 0.66
CDK1 P06493 3/20 0.66
CCNB1 P14635 3/20 0.66
PRKACA P17612 3/20 0.66
PRKACG P22612 3/20 0.66
PRKACB P22694 3/20 0.66
GSK3B P49841 3/20 0.66
CCNB3 Q8WWL7 3/20 0.66
CSNK1A1 P48729 2/20 0.66
CSNK1D P48730 2/20 0.66
CSNK1E P49674 2/20 0.66
CLK1 P49759 2/20 0.66
CSNK1G2 P78368 2/20 0.66
CSNK1G1 Q9HCP0 2/20 0.66
CYP1A1 P04798 1/20 0.66
CYP1A2 P05177 1/20 0.66
PIM1 P11309 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1839008 0.86 CCNT1 (0.67) CDK5CDK5R1PDPK1GSK3BCCNT1
SCHEMBL1836259 0.84 CCNT1 (0.76) CDK5CDK5R1PDPK1CCNT1CCNA2
SCHEMBL12572789 0.81 CDK2 (0.52) CDK5CDK5R1PDPK1CCNB2CDK1
SCHEMBL1841954 0.81 CCNT1 (0.77) CDK5CDK5R1PDPK1GSK3BCCNT1
SCHEMBL1843060 0.81 CCNT1 (0.80) PDPK1CCNT1CCNA2CDK2CDK9
SCHEMBL1604060 0.80 CDK2 (0.67) CDK5PDPK1CDK1PRKACAGSK3B
Meridianin C SCHEMBL1612228 0.80 GSK3B (1.00) CDK5CDK5R1PDPK1CCNB2CDK1
Meridianin C SCHEMBL30369326 0.80 GSK3B (1.00) CDK5CDK5R1PDPK1CCNB2CDK1
SCHEMBL2239305 0.79 CLK1 (0.66) CDK5CDK5R1PDPK1GSK3BCLK1
SCHEMBL18941992 0.79 CCNT1 (1.00) GSK3BCCNT1CCNA2CDK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113816957-B 4- (7-azaindole) -2-aminopyrimidine compounds and application thereof 浙江工业大学 2023-04-07 CN disclosed
CN-113816957-A 4- (7-azaindole) -2-aminopyrimidine compounds and application thereof 浙江工业大学 2021-12-21 CN disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 CDK5 24/4885CDK5R1 41/4885PDPK1 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.